Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies
about
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing.Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomesDebrisoquine and mephenytoin oxidation in Sinhalese: a population studyInfluence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.Timolol metabolism and debrisoquine oxidation polymorphism: a population study.Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.Perturbation of paracetamol urinary metabolic ratios by urine flow rate.Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.Sparteine oxidation polymorphism in Greenlanders living in DenmarkPharmacogenetics and response to beta-adrenergic receptor antagonists in heart failure.Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.The clinical role of genetic polymorphisms in drug-metabolizing enzymes.Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.Differences in drug metabolism polymorphism between Orientals and Caucasians.Prediction of xenobiotic metabolism by non-invasive methods.CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.Variability in drug metabolism: importance of genetic constitution.Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs.Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.Metoprolol oxidation in a Japanese population: evidence for only one poor metaboliser among 262 subjects.An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.Metoprolol oxidation polymorphism in Brazilian elderly cardiac patients.Genetically determined polymorphisms in drug oxidation.Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.Exploring micropollutant biotransformation in three freshwater phytoplankton species.
P2860
Q30976703-485D9681-3D50-4121-A476-1C177C9A0D3EQ34188511-57C82312-2C8D-40E5-ACCA-F415705E3047Q34345780-D58E26FC-864A-4C99-AF9C-789327705065Q34346464-5AB14F88-FB53-4732-B73F-B35B16970344Q34346631-DF7A30F1-8D49-47EB-92F1-06DE571459A0Q34357888-83D43F0C-7D7E-4CEC-8F64-B2CD76665CB9Q34359016-0FDB3787-7E1A-4047-8923-78E13F21162FQ34397032-FF922CAF-3F3E-499E-99BE-9E8975BB7B24Q34398153-70BF9FEB-2118-47FB-A9E9-F60BCBBB32C1Q34403268-32EBE999-C820-4AB0-AF30-6BE8888BC378Q34417711-45B09A04-736D-4271-8D60-B45990DAD6D0Q34448025-A4DC14C0-E0F0-49A6-9DC5-4DDD2E1AA03BQ36056712-23FBC9AB-0C1F-4A6A-81C9-199B896B20CCQ36440966-A79FD1E9-BE83-481B-ACDB-1A15D824BD2CQ36720920-D4291B36-99E9-48A8-BE2D-38AA988EF46BQ36792630-B28390B3-F3F4-4E9D-9D2E-701017D4B66BQ36840621-655C4989-6631-47E6-B895-99DC99CE241DQ37611786-1D0C9D8E-87C9-4C77-B851-F191E2AFD279Q37782957-1AC5D7AE-C8B8-4DC7-A19B-F15C8AF57F59Q37783192-5BB57638-B3BB-43A4-B5F6-345555400D9DQ37829237-7E12AC2A-41D7-4B1D-A782-6B2D8849785EQ39127810-CD3A9528-C551-4779-8C35-5BD3DCB62B11Q39656631-8525840F-C3EC-476F-804B-5407E14DF8CCQ39944445-994B4473-C2DF-4DD4-8AF3-8A4D88D66E4DQ41834120-E2650CEB-640F-4590-A069-0F45D0519992Q41944104-3C3F9629-9CD7-4330-AC8E-1732F4EE20E5Q42250442-EBCEB3EC-E8C0-4FB9-8F1B-E1F73D401B26Q42285085-89A4C236-0871-476D-8B0E-09EDDDC68F8FQ43060437-DE528F06-B327-4BAB-807D-D8466B0ADA4DQ43423712-D6710FF6-4164-4772-8927-ED5EB1F7C227Q44202468-B91DD960-9241-469D-A225-A90B9824950EQ44772582-8C7A7B80-2CEC-49E9-9619-F90705955822Q44947499-6A884E64-7944-4A43-84AA-1FAFC8C48616Q45151691-0212CE46-6253-43CF-BECF-C098568DFFBFQ45279397-7EB011C3-886C-4AF8-89A5-EF7A072ABB61Q45741959-96BFD194-8B53-4B0F-9A06-72A6C0086B7CQ46191457-C18E84B1-5CF9-4C0F-97D5-C52A54DB532BQ46226201-FA0DFE7B-053D-4E51-AE80-DE42D7475BAFQ46332841-7370E8D0-82EE-47B1-9350-7EFC8B15827BQ46369142-2E08DE94-2CF6-48B4-B2ED-FEB6D97CB3F6
P2860
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies
description
1985 nî lūn-bûn
@nan
1985 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Metoprolol metabolism and debr ...... -population and family studies
@ast
Metoprolol metabolism and debr ...... -population and family studies
@en
Metoprolol metabolism and debr ...... -population and family studies
@nl
type
label
Metoprolol metabolism and debr ...... -population and family studies
@ast
Metoprolol metabolism and debr ...... -population and family studies
@en
Metoprolol metabolism and debr ...... -population and family studies
@nl
prefLabel
Metoprolol metabolism and debr ...... -population and family studies
@ast
Metoprolol metabolism and debr ...... -population and family studies
@en
Metoprolol metabolism and debr ...... -population and family studies
@nl
P2093
P2860
P1476
Metoprolol metabolism and debr ...... -population and family studies
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1985.TB05112.X
P407
P577
1985-12-01T00:00:00Z